<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05007483</url>
  </required_header>
  <id_info>
    <org_study_id>202104639</org_study_id>
    <nct_id>NCT05007483</nct_id>
  </id_info>
  <brief_title>Efficacy of Diet on Quality of Life in Multiple Sclerosis</brief_title>
  <acronym>EDQ</acronym>
  <official_title>Efficacy of Diet on Quality of Life in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Terry L. Wahls</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching goal of this project is to critically evaluate the efficacy of incorporating&#xD;
      dietary guidance within multiple sclerosis (MS) care for improving long-term quality of life&#xD;
      (QoL) compared to usual care. The primary objective of this study is to evaluate the effect&#xD;
      of two dietary interventions (time restricted olive oil based (TROO) ketogenic and modified&#xD;
      Paleolithic elimination) on MS QoL compared to usual care control (Dietary Guidelines for&#xD;
      America), and the secondary objectives and the long-term effects on, motor function,&#xD;
      low-contrast vision sensitivity, fatigue, mood, and disease activity assessed by brain&#xD;
      imaging.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the United States, MS affects nearly 1 million people with a 2.8:1 female to male ratio&#xD;
      and the highest incidence rates among whites and African Americans. The economic cost of&#xD;
      managing MS is substantial. In the U.S., the total medical costs for patients with MS&#xD;
      increased from $116 million in 2002 to $198 million in 2013. MS is a chronic,&#xD;
      neuroinflammatory, and neurodegenerative disease-causing symptoms of pain, fatigue, and&#xD;
      changes in vision, cognition, and movement that greatly reduce quality of life (QoL) and the&#xD;
      ability to maintain employment.&#xD;
&#xD;
      The overarching goal of this project is to critically evaluate the efficacy of incorporating&#xD;
      dietary guidance within multiple sclerosis (MS) care for improving long-term quality of life&#xD;
      (QoL) compared to usual care. The primary objective of this study is to evaluate the effect&#xD;
      of two dietary interventions (time restricted olive oil based (TROO) ketogenic and modified&#xD;
      Paleolithic elimination) on MS QoL compared to usual care control (Dietary Guidelines for&#xD;
      America), and the secondary objectives and the long-term effects on, motor function,&#xD;
      low-contrast vision sensitivity, fatigue, mood, and disease activity assessed by brain&#xD;
      imaging.&#xD;
&#xD;
      The proposed study will consist of study participants attending 2 in-person site visits, one&#xD;
      at baseline and the other 2 years later (months 0, and 24) with online surveys every 2 months&#xD;
      (months 0-24).&#xD;
&#xD;
      This study will use a randomized single-blind controlled design to test the short-term (6&#xD;
      months) and long-term (an additional 18 months) impact of the intervention diets on symptoms&#xD;
      of MS including QoL and related outcomes stated above. We will use a fourteen-day run-in&#xD;
      period to identify participants who are most likely to be successful in completing study&#xD;
      procedures; this process has been effective in our previous studies. Participants who&#xD;
      successfully complete all baseline self-reported outcomes and follow all study procedures&#xD;
      during the seven-day run-in period will be scheduled for an on-site baseline visit for&#xD;
      randomization to intervention diets (time restricted olive oil based (TROO) ketogenic and&#xD;
      modified Paleolithic elimination) or usual care control (Dietary Guidelines for America).&#xD;
&#xD;
      On-site study visits will include blood draws, motor, cognitive, vision function assessments,&#xD;
      and MRI. Motor assessments will include a 6-minute walk test, 25-foot walk test, 9-hole&#xD;
      pegboard to test hand function, symbol digit exercise to test thinking functions, and low&#xD;
      contrast vision sensitivity to test vision. The study participant will be escorted to the MRI&#xD;
      unit to complete a non-contrast MRI of the brain. At the baseline visit, participants will be&#xD;
      randomized. Participants assigned to the intervention diets will be given intervention&#xD;
      specific educational materials including shopping lists, example menus and recipes, and the&#xD;
      study supplements. Study participants randomized to the control arm will receive emails&#xD;
      and/or text messages (approximately 3-6 weeks) to receive resources with websites for the&#xD;
      Dietary Guidelines of America, and recent multiple sclerosis-related research that does not&#xD;
      involve diet.&#xD;
&#xD;
      Study team will provide fish oil, essential fatty acids, and phosphatidylcholine to the two&#xD;
      intervention groups only. The participant will be scheduled for a Zoom video conference&#xD;
      meeting with the assigned registered dietitian to review the assigned study diet.&#xD;
&#xD;
      In addition, subjects will collect saliva specimens for microbiome analysis at each of the 2&#xD;
      site study visits (month 0 and 24).&#xD;
&#xD;
      24-hour dietary recalls will be collected by a study registered dietitian (RD) (who did not&#xD;
      provide training on the respective participants assigned study diet) on three non-consecutive&#xD;
      days at baseline, and one per month, at months 10-12, and 22-24. Participants will be given a&#xD;
      3-month window to complete dietary recalls in the event of scheduling conflicts. Participants&#xD;
      will be instructed to record key study diet components each day using a study specific&#xD;
      questionnaire in the study related (MyCap) application on their smart device.&#xD;
&#xD;
      The online questionnaires sent to participants every 2 months will also be used to track&#xD;
      supplement intake, medication use, and details about health &amp; life events, MS symptoms,&#xD;
      fatigue, quality of life, doctor's appointment, and side effects they may be experiencing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled study design</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>Assessors and principle investigator masked</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)</measure>
    <time_frame>baseline to 6 Months</time_frame>
    <description>Change in (MS 54 QoL MH) survey questions mean scores, range 0-100, higher number is better.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)</measure>
    <time_frame>baseline to 12 Months</time_frame>
    <description>Change in (MS 54 QoL MH) survey questions mean scores, range 0-100, higher number is better.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)</measure>
    <time_frame>baseline to 18 Months</time_frame>
    <description>Change in (MS 54 QoL MH) survey questions mean scores, range 0-100, higher number is better.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)</measure>
    <time_frame>baseline to 24 Months</time_frame>
    <description>Change in (MS 54 QoL MH) survey questions mean scores, range 0-100, higher number is better.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)</measure>
    <time_frame>baseline to 6 Months</time_frame>
    <description>Change in (MS 54 QoL PH) survey questions mean scores, range 0-100, higher number is better.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)</measure>
    <time_frame>baseline to 12 Months</time_frame>
    <description>Change in (MS 54 QoL PH) survey questions mean scores, range 0-100, higher number is better.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)</measure>
    <time_frame>baseline to 18 Months</time_frame>
    <description>Change in (MS 54 QoL PH) survey questions mean scores, range 0-100, higher number is better.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)</measure>
    <time_frame>baseline to 24 Months</time_frame>
    <description>Change in (MS 54 QoL PH) survey questions mean scores, range 0-100, higher number is better.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Fatigue Impact Scale (MFIS)</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Change in MFIS survey questions, scores range from 0-84, lower score is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Fatigue Impact Scale (MFIS)</measure>
    <time_frame>baseline to 12 months</time_frame>
    <description>Change in MFIS survey questions, scores range from 0-84, lower score is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Fatigue Impact Scale (MFIS)</measure>
    <time_frame>baseline to 18 months</time_frame>
    <description>Change in MFIS survey questions, scores range from 0-84, lower score is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Fatigue Impact Scale (MFIS)</measure>
    <time_frame>baseline to 24 months</time_frame>
    <description>Change in MFIS survey questions, scores range from 0-84, lower score is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety Depression Scale (HADS)</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Change in HADS survey question score, a 14 question scale ranging from 0-3 with zero being being low or no occurrence and 3 being high occurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety Depression Scale (HADS)</measure>
    <time_frame>baseline to 12 months</time_frame>
    <description>Change in HADS survey question score, a 14 question scale ranging from 0-3 with zero being being low or no occurrence and 3 being high occurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety Depression Scale (HADS)</measure>
    <time_frame>baseline to 18 months</time_frame>
    <description>Change in HADS survey question score, a 14 question scale ranging from 0-3 with zero being being low or no occurrence and 3 being high occurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety Depression Scale (HADS)</measure>
    <time_frame>baseline to 24 months</time_frame>
    <description>Change in HADS survey question score, a 14 question scale ranging from 0-3 with zero being being low or no occurrence and 3 being high occurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Severity Scale score (FSS)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change in FSS survey question mean scores, scores range from 1-7, lower is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Severity Scale score (FSS)</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Change in FSS survey question mean scores, scores range from 1-7, lower is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Severity Scale score (FSS)</measure>
    <time_frame>Baseline to 18 months</time_frame>
    <description>Change in FSS survey question mean scores, scores range from 1-7, lower is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Severity Scale score (FSS)</measure>
    <time_frame>Baseline to 24 months</time_frame>
    <description>Change in FSS survey question mean scores, scores range from 1-7, lower is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain volume as measured by non contrast magnetic resonance imaging (MRI)</measure>
    <time_frame>baseline to 24 months</time_frame>
    <description>Change in MRI grey matter brain volume, more is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain lesions as measured by non contrast magnetic resonance imaging (MRI)</measure>
    <time_frame>baseline to 24 months</time_frame>
    <description>Change in inflammatory lesions numbers as measured by non contrast brain MRI, fewer is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed 25 foot walk test</measure>
    <time_frame>baseline to 24 months</time_frame>
    <description>seconds required to walk 25 feet, lower is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9 Hole peg board test</measure>
    <time_frame>baseline to 24 months</time_frame>
    <description>seconds require to move 9 pegs to various locations on a peg board, fewer seconds is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low contrast visual acuity</measure>
    <time_frame>baseline to 24 months</time_frame>
    <description>A measure of best corrected vision, measure is log minimal angle of resolution at 2.5% contrast. Lower number is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour dietary intake recalls</measure>
    <time_frame>baseline to 12 months</time_frame>
    <description>Change in dietary intake measured by dietary interview conducted via telephone call; more nutrients meeting recommended dietary allowance is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour dietary intake recalls</measure>
    <time_frame>baseline to 24 months</time_frame>
    <description>Change in dietary intake measured by dietary interview conducted via telephone call; more nutrients meeting recommended dietary allowance is better.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>Group 1 (Modified paleolithic elimination diet).</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modified paleolithic elimination diet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (TROO)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Time Restricted Olive Oil Based (TROO) Ketogenic Diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dietary Guidelines for Americans Diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>BodyBio Balance Oil</intervention_name>
    <description>nutraceutical supplement</description>
    <arm_group_label>Group 1 (Modified paleolithic elimination diet).</arm_group_label>
    <arm_group_label>Group 2 (TROO)</arm_group_label>
    <other_name>1400 mg linoleic acid/350 mg linolenic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Kirunal Fish Oil</intervention_name>
    <description>nutraceutical supplement</description>
    <arm_group_label>Group 1 (Modified paleolithic elimination diet).</arm_group_label>
    <arm_group_label>Group 2 (TROO)</arm_group_label>
    <other_name>315 mg eicosapentanoic acid/ 105 mg docosahexaenoic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>BodyBio PC</intervention_name>
    <description>nutraceutical supplement</description>
    <arm_group_label>Group 1 (Modified paleolithic elimination diet).</arm_group_label>
    <arm_group_label>Group 2 (TROO)</arm_group_label>
    <other_name>1300 mg phosphatidylcholine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Modified Paleolithic Elimination diet</intervention_name>
    <description>Complete elimination of all gluten-, dairy-, and egg-containing foods.&#xD;
Increase fruit and vegetable intake to 6-9 servings/day comprising of 2-3 servings each of the following categories: intensely colored, sulfur-rich, and leafy greens.&#xD;
Consume 6-12 ounces/day protein including organ meats and fatty fish.&#xD;
Consume fermented foods daily.&#xD;
Consume daily servings of algae, seaweed, and nutritional yeast.</description>
    <arm_group_label>Group 1 (Modified paleolithic elimination diet).</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Time Restricted Olive Oil Based (TROO) Ketogenic Diet</intervention_name>
    <description>Restriction of dietary carbohydrates to &lt; 50 grams/day.&#xD;
Use olive oil (cold-pressed extra virgin preferred) to increase fat intake to &gt;160 grams/day.&#xD;
Consume &lt;100 grams/day protein.&#xD;
Limit dairy to 2 servings/day of whole fat options (completely exclude reduced fat dairy).&#xD;
Consume at least 3 servings/day non-starchy vegetables.</description>
    <arm_group_label>Group 2 (TROO)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dietary Guidelines for Americans Diet</intervention_name>
    <description>Limit sodium to &lt; 2,300 mg/day.&#xD;
Limit added sugar and saturated fat intake to &lt;10% of kcal/day, respectively.&#xD;
Consume 5 servings of fruits and vegetables per day.&#xD;
Consume 6-9 ounce equivalents/day of grains, making at least half whole grain options.&#xD;
Consume 3 servings of reduced fat dairy per day.&#xD;
Consume 6 ounces/day protein foods.</description>
    <arm_group_label>Group 3 Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility for the run-in phase of the study:&#xD;
&#xD;
        Participants will be eligible to enroll in the fourteen-day run-in phase of the study if&#xD;
        they meet the following inclusion and exclusion criteria:&#xD;
&#xD;
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  A definitive diagnosis of RRMS based on the 2017 revised McDonald Criteria.&#xD;
&#xD;
          -  The ability to prepare, or availability of someone to prepare, home-cooked meals.&#xD;
&#xD;
          -  Must own a computer, smartphone, or tablet device that has internet access to complete&#xD;
             online surveys and capable of running study related applications.&#xD;
&#xD;
          -  Must be willing to follow study procedures outlined and explained to them.&#xD;
&#xD;
          -  Be between the ages of 18 to 70 at the time of consent.&#xD;
&#xD;
          -  Must be able to walk 25 feet without support.&#xD;
&#xD;
          -  Willingness to be randomized and follow any of the study diets (including the control&#xD;
             diet).&#xD;
&#xD;
          -  Must consent to sharing the clinical notes from their primary care and neurology&#xD;
             providers during the study period.&#xD;
&#xD;
          -  Must live within an approximate 500-mile radius of Iowa City OR live in one of the&#xD;
             following states: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri,&#xD;
             Nebraska, Ohio, South Dakota, or Wisconsin.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Moderate or severe mental impairment.&#xD;
&#xD;
          -  Use of insulin, Coumadin, weight loss medications such as orlistat that causes fat&#xD;
             malabsorption.&#xD;
&#xD;
          -  Worsening of symptoms resulting in the initiation or change of treatment including&#xD;
             steroids (solumedrol, prednisone, etc.) or disease-modifying medications in 12 weeks&#xD;
             prior to consent.&#xD;
&#xD;
          -  Treatment for cancer by radiation or chemotherapy in 12 months prior to consent, other&#xD;
             than skin cancer.&#xD;
&#xD;
          -  Diagnosis of clinically significant heart disease, liver disease, kidney disease, or&#xD;
             history of oxalate kidney stones.&#xD;
&#xD;
          -  Diagnosis of type II diabetes that does not have approval from treating physicians to&#xD;
             adopt any of the 3 study diets.&#xD;
&#xD;
          -  Clinical diagnosis of psychiatric disease that makes study adherence more difficult&#xD;
             (e.g., schizophrenia, bi-polar disease, severe depression and/or anxiety).&#xD;
&#xD;
          -  An active eating disorder such as anorexia, bulimia, binge eating, or orthorexia.&#xD;
&#xD;
          -  Measurement of BMI &lt;19 or &gt;40.&#xD;
&#xD;
          -  Confirmation of pregnancy or planning to become pregnant in the next 2 years.&#xD;
&#xD;
          -  History of diagnosed fat intolerance/malabsorption such as cholecystectomy or&#xD;
             uncontrolled exocrine pancreatic insufficiency.&#xD;
&#xD;
          -  Participation in another research study investigating MS treatments, diet, or&#xD;
             exercise.&#xD;
&#xD;
          -  Presence of a contraindication to completing a brain MRI or having claustrophobia&#xD;
             which interferes with completion of MRI studies without the use of sedation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terry L Wahls, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary Ehlinger, BS</last_name>
    <phone>319 384 5002</phone>
    <email>MSDietStudy@healthcare.uiowa.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Univeristy of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52246</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Arlene Miller, BA</last_name>
      <phone>319-356-4421</phone>
      <email>arelene-miller@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary Ehlinger, BS</last_name>
      <phone>319 384 5002</phone>
      <email>mary-ehlinger@uiowa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Terry Wahls, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linda Snetselaar, PhD, RD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wahls TL, Chenard CA, Snetselaar LG. Review of Two Popular Eating Plans within the Multiple Sclerosis Community: Low Saturated Fat and Modified Paleolithic. Nutrients. 2019 Feb 7;11(2). pii: E352. doi: 10.3390/nu11020352. Review.</citation>
    <PMID>30736445</PMID>
  </results_reference>
  <results_reference>
    <citation>Wahls T, Scott MO, Alshare Z, Rubenstein L, Darling W, Carr L, Smith K, Chenard CA, LaRocca N, Snetselaar L. Dietary approaches to treat MS-related fatigue: comparing the modified Paleolithic (Wahls Elimination) and low saturated fat (Swank) diets on perceived fatigue in persons with relapsing-remitting multiple sclerosis: study protocol for a randomized controlled trial. Trials. 2018 Jun 4;19(1):309. doi: 10.1186/s13063-018-2680-x.</citation>
    <PMID>29866196</PMID>
  </results_reference>
  <results_reference>
    <citation>Chenard CA, Rubenstein LM, Snetselaar LG, Wahls TL. Nutrient Composition Comparison between a Modified Paleolithic Diet for Multiple Sclerosis and the Recommended Healthy U.S.-Style Eating Pattern. Nutrients. 2019 Mar 1;11(3). pii: E537. doi: 10.3390/nu11030537.</citation>
    <PMID>30832289</PMID>
  </results_reference>
  <results_reference>
    <citation>Titcomb TJ, Bisht B, Moore DD 3rd, Chhonker YS, Murry DJ, Snetselaar LG, Wahls TL. Eating Pattern and Nutritional Risks among People with Multiple Sclerosis Following a Modified Paleolithic Diet. Nutrients. 2020 Jun 20;12(6). pii: E1844. doi: 10.3390/nu12061844.</citation>
    <PMID>32575774</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee JE, Bisht B, Hall MJ, Rubenstein LM, Louison R, Klein DT, Wahls TL. A Multimodal, Nonpharmacologic Intervention Improves Mood and Cognitive Function in People with Multiple Sclerosis. J Am Coll Nutr. 2017 Mar-Apr;36(3):150-168. doi: 10.1080/07315724.2016.1255160. Epub 2017 Apr 10.</citation>
    <PMID>28394724</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee JE, Titcomb TJ, Bisht B, Rubenstein LM, Louison R, Wahls TL. A Modified MCT-Based Ketogenic Diet Increases Plasma Î²-Hydroxybutyrate but Has Less Effect on Fatigue and Quality of Life in People with Multiple Sclerosis Compared to a Modified Paleolithic Diet: A Waitlist-Controlled, Randomized Pilot Study. J Am Coll Nutr. 2021 Jan;40(1):13-25. doi: 10.1080/07315724.2020.1734988. Epub 2020 Mar 26.</citation>
    <PMID>32213121</PMID>
  </results_reference>
  <results_reference>
    <citation>Chenard CA, Rubenstein LM, Snetselaar LG, Wahls TL. Nutrient Composition Comparison between the Low Saturated Fat Swank Diet for Multiple Sclerosis and Healthy U.S.-Style Eating Pattern. Nutrients. 2019 Mar 13;11(3). pii: E616. doi: 10.3390/nu11030616.</citation>
    <PMID>30871265</PMID>
  </results_reference>
  <results_reference>
    <citation>Irish AK, Erickson CM, Wahls TL, Snetselaar LG, Darling WG. Randomized control trial evaluation of a modified Paleolithic dietary intervention in the treatment of relapsing-remitting multiple sclerosis: a pilot study. Degener Neurol Neuromuscul Dis. 2017 Jan 4;7:1-18. doi: 10.2147/DNND.S116949. eCollection 2017.</citation>
    <PMID>30050374</PMID>
  </results_reference>
  <results_reference>
    <citation>Bisht B, Darling WG, Grossmann RE, Shivapour ET, Lutgendorf SK, Snetselaar LG, Hall MJ, Zimmerman MB, Wahls TL. A multimodal intervention for patients with secondary progressive multiple sclerosis: feasibility and effect on fatigue. J Altern Complement Med. 2014 May;20(5):347-55. doi: 10.1089/acm.2013.0188. Epub 2014 Jan 29.</citation>
    <PMID>24476345</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 9, 2021</study_first_submitted>
  <study_first_submitted_qc>August 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Terry L. Wahls</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>dietary</keyword>
  <keyword>nutrition</keyword>
  <keyword>fatigue</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

